News Updates
Scope

Wed, May 27, 2026

1 updates
JAZZ
5:00 PM

Phase 3 HERIZON-GEA-01 Results Published in The New England Journal of Medicine Show Durable and Consistent Survival Benefit with Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA

Expanded safety, subgroup, progression-free survival sensitivity and subsequent therapy analyses further characterize the consistency and durability of outcomes observed with zanidatamab-containing combinations in the first-line setting Additional subgroup analyses to be presented at the 2026 ASCO

Presentation / Abstract • Phase 3ASCO oral presentation Fri, May 29, 2026jazzpharmaceuticals.com

Tue, May 12, 2026

1 updates
JAZZ
4:15 PM

Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences

DUBLIN, May 12, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that company management will participate in fireside chats at the following investor conferences: 2026 RBC Global Healthcare Conference on Tuesday, May 19, 2026 at 8:00 a.m.

jazzpharmaceuticals.com

Tue, May 5, 2026

1 updates
JAZZ
4:05 PM

Jazz Pharmaceuticals Announces First Quarter 2026 Financial Results

– Strong commercial execution across franchises with total revenues of $1.1 billion (+19% YoY) – – Zanidatamab HER2+ 1L GEA sBLA granted Priority Review; PDUFA date of August 25, 2026 – – Xywav ® revenues grew 18% YoY with 425 net patient adds – – Epidiolex ® revenues grew 15% YoY– – Company

jazzpharmaceuticals.com

Mon, Apr 27, 2026

1 updates
JAZZ
7:45 AM

Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA

Prescription Drug User Fee Act (PDUFA) date set for August 25, 2026 For U.S. media and investors only DUBLIN, April 27, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) accepted for filing with Priority Review the

jazzpharmaceuticals.com

Tue, Apr 21, 2026

2 updates
JAZZ
4:05 PM

Jazz Pharmaceuticals to Present Data at ASCO 2026 Highlighting Advancements for Ziihera® (zanidatamab-hrii) in Gastroesophageal Adenocarcinoma and Zepzelca® (lurbinectedin)

Rapid oral presentation of PD-L1 subgroup data from HERIZON-GEA-01 evaluating zanidatamab combinations, and additional analyses of tolerability, biomarker response and real-world treatment patterns in HER2+ GEA For U.S. media and investors only DUBLIN, April 21, 2026 /PRNewswire/ -- Jazz

Presentation / Abstract • Phase 3jazzpharmaceuticals.com

Thu, Apr 9, 2026

1 updates
JAZZ
7:45 AM

Jazz Pharmaceuticals to Present Research on Epidiolex® (cannabidiol) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution at the 2026 American Academy of Neurology Annual Meeting

Six abstracts, including one oral presentation, underscore Jazz's ongoing commitment to generating real- world evidence addressing rare neurological disorders, including rare and severe forms of epilepsy and sleep disorders For U.S. media and investors only DUBLIN, April 9, 2026 /PRNewswire/

Presentation / Abstract • Phase 4jazzpharmaceuticals.com

Wed, Apr 1, 2026

1 updates
JAZZ
4:15 PM

Jazz Pharmaceuticals to Participate in Needham Virtual Healthcare Conference

DUBLIN, April 1, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the 25 th Annual Needham Healthcare Conference. Company management will participate in a fireside chat on Wednesday, April 15, 2026, at 8:45 a.m. PT / 11:45 a.m.

jazzpharmaceuticals.com

Wed, Mar 18, 2026

1 updates